{
    "Trade/Device Name(s)": [
        "Bioland Blood Glucose Monitoring System",
        "Bioland Blood Glucose Meter",
        "Bioland Blood Glucose Test Strips",
        "Bioland Glucose Control Solution"
    ],
    "Submitter Information": "Bioland Technology Ltd.",
    "510(k) Number": "K191657",
    "Predicate Device Reference 510(k) Number(s)": [
        "K113077"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NBW"
    ],
    "Summary Letter Date": "March 20, 2020",
    "Summary Letter Received Date": "June 21, 2019",
    "Submission Date": "June 12, 2019",
    "Regulation Number(s)": [
        "21 CFR 862.1345"
    ],
    "Regulation Name(s)": [
        "Glucose Test System"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Fresh capillary whole blood"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Bioland Blood Glucose Meter"
    ],
    "Method(s)/Technology(ies)": [
        "Electrochemical biosensor",
        "Amperometric technology using glucose oxidase"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "System",
        "Meter",
        "Test Strips",
        "Control Solution"
    ],
    "Document Summary": "FDA 510(k) summary for Bioland Blood Glucose Monitoring System employing electrochemical biosensor technology for self-monitoring of blood glucose in diabetic patients",
    "Indications for Use Summary": "Quantitative measurement of glucose in fresh capillary whole blood drawn from the fingertip for self-testing by people with diabetes at home as an aid to monitor effectiveness of diabetes control; not for diagnosis or screening or use in neonates",
    "fda_folder": "Clinical Chemistry"
}